Literature DB >> 23027103

Comparison of triphasic waves and epileptic discharges in one patient with genetic epilepsy.

Peter W Kaplan1, Dan K Schlattman.   

Abstract

Genetic epilepsies with generalized spike-wave complexes (GSWCs) and encephalopathy triphasic waves (TWs) may resemble each other and have three phases per complex. Electroencephalographic (EEG) interpretation is subjective, and EEGers have noted "TWs" in cases labeled nonconvulsive status epilepticus (NCSE). Direct comparison of both wave forms under the same conditions is rarely possible. In a single patient with generalized spike waves who developed hepatic TWs, morphologic characteristics of both were compared, and it was found that GSWCs have higher frequency first, second, and third phases; steeper phase 2 slope; and briefer after-going slow waves maximal at F3 to F4. Total complex duration was approximately 0.12 seconds. The TWs had dominant high-voltage phases 2 and 3 located more posteriorly, in the frontocentral region, lasting an average of approximately 0.32 seconds. These morphologic distinctions may help differentiate TWs from GSWCs.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23027103     DOI: 10.1097/WNP.0b013e31826bde70

Source DB:  PubMed          Journal:  J Clin Neurophysiol        ISSN: 0736-0258            Impact factor:   2.177


  3 in total

1.  Triphasic Waves: Swinging the Pendulum Back in this Diagnostic Dilemma.

Authors:  Adriana Bermeo-Ovalle
Journal:  Epilepsy Curr       Date:  2017 Jan-Feb       Impact factor: 7.500

2.  Spike densities of the amygdala and neocortex reflect progression of kindled motor seizures.

Authors:  Yu-Lin Wang; Sheng-Fu Liang; Alvin W Y Su; Fu-Zen Shaw
Journal:  Med Biol Eng Comput       Date:  2017-07-04       Impact factor: 2.602

3.  Cefepime-induced encephalopathy: Neural mass modeling of triphasic wave-like generalized periodic discharges with a high negative component (Tri-HNC).

Authors:  Hidetaka Tamune; Yu Hamamoto; Naofumi Aso; Naoki Yamamoto
Journal:  Psychiatry Clin Neurosci       Date:  2018-12-12       Impact factor: 5.188

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.